Granahan Investment Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Granahan Investment Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-241,853	Closed	-$128K	–	200
2019 Q4	$128K	Buy	241,853 +1,082	+0.4%	+$2.62K	0.01%	181
2019 Q3	$917K	Buy	240,771 +18,200	+8%	+$65.6K	0.05%	160
2019 Q2	$1.48M	Sell	222,571 -6,459	-3%	-$24.6K	0.07%	157
2019 Q1	$813K	Buy	229,030 +166,831	+268%	+$905K	0.04%	176
2018 Q4	$247K	Sell	62,199 -1,113	-2%	-$14.2K	0.02%	187
2018 Q3	$1.25M	Buy	63,312 +2,474	+4%	+$62.5K	0.07%	176
2018 Q2	$1.93M	Buy	+60,838	New	+$2.19M	0.12%	165

Granahan Investment Management's MLNT Position: Q1 2020 in Review

Granahan Investment Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 241,853 shares — an estimated $128K sold.

Granahan Investment Management first reported a position in MLNT in Q2 2018 and held it in 7 quarters. The position peaked at $1.93M in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Granahan Investment Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Granahan Investment Management sold 241,853 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $128K.
Granahan Investment Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Granahan Investment Management's Melinta Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Granahan Investment Management's 13F filing for Q1 2020, filed 12 May 2020.